Serum levels of prostate specific-antigen (PSA) have long been used as a biomarker for screening and diagnosing PCa, but the poor specificity of this biomarker has led to unnecessary biopsy and severe overtreatment of low-risk PCa (5). Here, KLK3 is linked to posterior cortical atrophy.